Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 751 Cr.
- Current Price ₹ 31.2
- High / Low ₹ 53.5 / 6.41
- Stock P/E 41.8
- Book Value ₹ 5.46
- Dividend Yield 0.00 %
- ROCE 15.3 %
- ROE 14.8 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 69.6% CAGR over last 5 years
Cons
- Stock is trading at 5.84 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.5% over last 3 years.
- Debtor days have increased from 92.3 to 116 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 55 | 88 | 139 | 148 | 193 | 357 | 461 | 466 | 503 | |
| 55 | 87 | 135 | 143 | 186 | 346 | 446 | 443 | 464 | |
| Operating Profit | 1 | 1 | 4 | 5 | 7 | 11 | 15 | 23 | 38 |
| OPM % | 1% | 1% | 3% | 3% | 4% | 3% | 3% | 5% | 8% |
| 0 | 2 | 1 | 0 | 0 | 0 | 1 | 3 | 0 | |
| Interest | 0 | 1 | 2 | 3 | 3 | 3 | 5 | 9 | 16 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 1 | 3 | 2 | 4 | 7 | 10 | 15 | 21 |
| Tax % | 40% | 24% | 28% | 26% | 25% | 26% | 26% | 25% | 25% |
| 0 | 1 | 2 | 1 | 3 | 5 | 7 | 11 | 16 | |
| EPS in Rs | 0.07 | 0.16 | 0.25 | 0.13 | 0.28 | 0.54 | 0.29 | 0.47 | 0.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 50% |
| TTM: | 58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 398% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 5 | 10 | 10 | 10 | 10 | 24 | 24 | 24 |
| Reserves | 1 | 4 | 9 | 10 | 13 | 20 | 77 | 88 | 107 |
| 6 | 10 | 14 | 21 | 30 | 31 | 34 | 107 | 173 | |
| 11 | 12 | 17 | 18 | 47 | 77 | 97 | 66 | 96 | |
| Total Liabilities | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 285 | 400 |
| 0 | 0 | 2 | 6 | 6 | 6 | 20 | 21 | 20 | |
| CWIP | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 2 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 17 | 34 |
| 20 | 31 | 47 | 53 | 93 | 130 | 200 | 245 | 341 | |
| Total Assets | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 285 | 400 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -2 | -0 | -1 | 1 | 3 | -4 | -29 | 8 | 35 | |
| -0 | -0 | -4 | -3 | -1 | -2 | -26 | -7 | -20 | |
| 2 | -1 | 8 | -0 | -2 | 4 | 66 | -12 | -14 | |
| Net Cash Flow | 0 | -1 | 3 | -2 | -0 | -1 | 11 | -12 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 71 | 68 | 66 | 114 | 75 | 64 | 96 | 116 |
| Inventory Days | 23 | 28 | 29 | 46 | 49 | 51 | 63 | 73 | 114 |
| Days Payable | 75 | 49 | 45 | 40 | 90 | 80 | 78 | 49 | 73 |
| Cash Conversion Cycle | 40 | 51 | 52 | 72 | 73 | 46 | 50 | 120 | 157 |
| Working Capital Days | 42 | 52 | 53 | 69 | 75 | 53 | 71 | 139 | 173 |
| ROCE % | 16% | 20% | 12% | 15% | 19% | 15% | 14% | 15% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015
4 Jun - Received One Star Export House certificate valid May 2025 to March 2030.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report confirms regulatory compliance for FY ended March 31, 2025; 9 lakh convertible warrants issued.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
29 May - The Company will be meeting Investors / Analysts on Tuesday, 03-June-2025. Kindly take the same on record.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 May - Newspaper Advertisement - Notice of Extra Ordinary General Meeting to be held on 12th June, 2025
-
Extraordinary General Meeting On 12/June/2025
16 May - EGM on June 12, 2025 to approve Rs.2500 Cr borrowing, charge creation, and related party transactions.
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals